🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

ANI Pharmaceuticals, Inc. ANIP R2KR3KPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.anipharmaceuticals.com
Company Profile ↓
$72.61
-18.18% 1Y
Mkt Cap$1.67B
P/E15.72
P/B2.65
52W High$98.81
52W Low$70.16
Book Value$27.87
EPS (TTM)$4.62

Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.5%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 66.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 54.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 15.7, below the sector median of 25.4.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $883.37M (+43.8% YoY); net profit $78.34M.
  • Trailing 12 Months Year-on-year growth — revenue +25.9%, earnings +191.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 54.8%, profit CAGR 66.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:54.80%
1 Year:25.90%

Compounded Profit Growth

5 Years:66.65%
1 Year:191.10%

Stock Price Performance

1 Year:-18.18%
6 Months:-7.67%
3 Months:-7.35%
1 Month:-1.93%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 9% of range
$70.16 $98.81
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)48.63 · Neutral
Price Performance
1M-1.93%
3M-7.35%
6M-7.67%
1Y-18.18%
Valuation vs Sector

P/E of 15.72 is below the sector median of 25.45 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.5%.
  • Compounding revenue at 54.8% over 5 years.
  • Profit CAGR of 66.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 26.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
15.72
Industry PE
25.45
Forward P/E
6.98
PEG Ratio
1.77
Book Value
$27.87
Price to Book
2.65
P/S
1.73
EV/EBITDA
8.55
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
54.80%
Profit 5Y
66.65%
Revenue (YoY)
25.90%
Earnings (YoY)
191.10%

Profitability & Returns

ROCE
6.99%
ROE
20.46%
ROA
5.45%
Profit Margin
11.07%
Op Margin
14.97%
Gross Margin
60.40%
EPS (Latest Qtr)
$1.05
EPS (TTM)
$4.62

Balance Sheet & Liquidity

Debt/Equity
1.05
Quick Ratio
2.30
Current Ratio
2.91
Debt
$626.03M
Total Assets
$1.49B
Current Assets
$747.08M
Working Capital
$475.00M

Ownership

Promoter Holding
5.42%
Chg in Prom Hold
-0.02%
FII / Inst Holding
107.26%
Chg in FII Hold
0.20%

Financial Snapshot

Enterprise Value
$1.67B
Total Revenue (TTM)
$978.38M
EBITDA
$209.41M
Free Cash Flow
$132.21M
Operating Cash Flow
$189.47M
Shares Outstanding
22.96M
Gross Margin
60.40%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ANIP ANI Pharmaceuticals, Inc. R2KR3KPHARMA 72.61 15.72 $1.67B 0.00% 6.99% 20.46% 54.80% 66.65%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -----36.63M44.76M48.16M-46.48M47.27M50.70M-52.89M54.36M51.34M47.97M49.77M48.47M52.98M57.25M54.52M48.62M52.06M64.48M73.86M83.82M106.79M116.55M131.83M137.43M138.04M--197.12M211.37M227.81M247.06M237.46M266.04M
Cost of Revenue ----------------------------------73.04M74.61M93.39M100.27M93.58M-
Gross Profit ----------------------------------124.08M136.76M134.42M146.79M143.88M-
Operating Expenses ----------------------------------109.98M121.59M111.59M117.66M105.17M-
Operating Income 6.27M5.67M5.19M7.92M1.30M4.62M6.99M9.33M7.38M6.54M7.26M10.11M11.45M4.40M9.29M7.33M-4.67M-7.84M-11.31M2.80M331.00K3.04M-15.55M-3.56M-19.20M-12.91M-5.00M9.89M12.40M17.95M20.31M5.17M--14.10M15.17M22.83M29.13M38.71M40.46M
EBITDA ----------------------------------48.36M39.24M61.16M58.50M64.91M-
Interest Expense ----------------------------------5.48M5.44M4.73M4.41M3.77M-
Pretax Income ----------------------------------19.99M10.53M33.80M31.48M40.22M-
Tax Provision ----------------------------------4.31M1.98M7.18M3.99M10.73M-
Net Income -1.35M1.12M2.54M-1.15M2.68M4.72M-2.25M2.78M5.04M-449.00K6.58M3.90M-4.83M-7.01M-12.34M434.00K-3.63M86.00K-14.11M-4.45M-20.13M-14.92M-8.60M1.44M6.25M9.94M18.21M-2.29M--15.68M8.55M26.62M27.49M29.49M24.71M
Diluted EPS 0.250.120.100.22-0.090.100.230.40-0.830.190.230.420.460.040.530.32-0.41-0.59-1.030.04-0.300.01-1.17-0.37-1.27-0.94-0.550.060.290.450.82-0.14--0.690.361.131.181.281.05
R&D Expense -966.00K764.00K1.04M-1.62M2.17M2.63M-2.10M5.14M4.67M-4.37M5.77M4.98M-6.34M3.04M2.94M-2.97M2.81M2.46M5.27M4.17M7.66M5.92M7.37M11.12M10.51M7.30M10.13M-10.56M16.54M12.30M-10.60M14.75M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.26M2.47M435.16K20.37M30.08M55.97M76.32M128.62M176.84M201.58M206.55M208.47M-316.38M486.82M614.38M883.37M
Cost of Revenue -------------138.78M181.51M250.21M341.31M
Gross Profit -------------177.60M305.30M364.17M542.06M
Operating Expenses -------------203.33M255.77M361.95M460.83M
Operating Income ----42.00K898.00K20.01M32.70M20.08M28.33M35.36M16.35M-16.02M--25.73M49.53M2.22M81.23M
EBITDA -------------25.04M106.60M63.12M207.27M
Interest Expense -------------28.05M26.94M17.60M20.06M
Pretax Income --------------62.66M19.87M-22.21M95.79M
Tax Provision --------------14.77M1.09M-3.69M17.45M
Net Income -47.53M-46.20M-51.61M-1.51M301.00K28.75M15.38M3.93M-1.08M15.49M6.09M-22.55M--47.90M18.78M-18.52M78.34M
Diluted EPS -1.40-4.21-3.15-1.27-0.922.591.320.34-0.091.300.50-1.88--3.050.85-1.043.32
R&D Expense 13.68M39.71M44.18M1.16M1.71M2.68M2.87M2.91M9.07M15.39M19.81M16.00M11.37M22.32M34.29M44.58M51.66M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --44.77M62.38M13.75M44.50M259.56M285.26M322.86M412.14M430.60M456.79M461.19M-760.09M904.42M1.28B1.44B
Current Assets --------------344.26M519.82M528.46M753.12M
Cash & Equivalents 11.76M29.86M38.16M011.00K11.11M169.04M154.68M27.36M31.14M43.01M62.33M7.86M-48.23M221.12M144.86M285.58M
Inventory --------------105.36M111.20M136.78M143.07M
Receivables --------------165.44M162.08M221.73M281.08M
Total Liabilities --25.62M24.56M10.59M3.54M119.77M125.18M153.22M237.38M233.34M244.00M265.49M-421.55M446.82M855.94M899.65M
Current Liabilities --8.18M7.23M7.71M3.54M13.23M11.76M31.95M39.23M165.55M61.68M78.56M-99.44M145.48M194.45M278.11M
Long Term Debt ------106.54M113.43M069.95M67.30M175.81M172.44M-285.67M284.82M614.92M599.77M
Total Debt --------------286.52M285.67M624.09M617.03M
Total Equity 13.83M15.83M19.15M-34.28M-42.72M40.96M139.78M160.08M169.65M174.76M197.26M212.79M195.70M-338.54M457.60M428.53M540.72M
Shares Outstanding --------------17.64M20.73M21.54M23.11M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----137.00K-5.48M22.03M17.26M27.47M39.42M67.07M45.63M15.27M--31.20M118.96M64.02M185.22M
Investing Cash Flow ------35.75M-32.68M-149.06M-107.99M-27.38M-27.55M-68.32M--15.74M-18.51M-404.72M-34.32M
Financing Cash Flow ---440.00K-3.69M171.65M1.07M-729.00K72.36M-27.82M1.25M-1.44M--5.13M67.44M264.94M-9.94M
Capital Expenditure -165.72K-63.44K-719.92K-292.00K-191.00K-1.12M-2.18M-4.57M-10.37M-5.74M-6.63M-6.13M--16.45M-18.51M-16.95M-34.32M
Free Cash Flow ----429.00K-5.67M20.91M15.08M22.91M29.05M61.33M39.00M9.13M--47.66M100.45M47.06M150.90M
Net Change in Cash --------------52.07M167.89M-75.76M140.96M
Share Buybacks ---0433.00K002.50M001.03M1.52M890.00K1.96M4.99M10.96M12.21M
Dividends Paid ----------00190.00K1.62M1.62M1.62M1.16M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------56.1%62.7%59.3%61.4%
Operating Margin % ----0.2%3.0%35.7%42.8%15.6%16.0%17.5%7.9%-7.7%--8.1%10.2%0.4%9.2%
Net Margin % -3,777.9%-1,867.1%-11,859.7%-7.4%1.0%51.4%20.1%3.1%-0.6%7.7%3.0%-10.8%--15.1%3.9%-3.0%8.9%
ROE % -300.2%-241.3%150.5%3.5%0.7%20.6%9.6%2.3%-0.6%7.9%2.9%-11.5%--14.1%4.1%-4.3%14.5%
ROCE % ----0.7%2.2%8.1%12.0%6.9%7.6%13.3%4.1%-4.2%--3.9%6.5%0.2%7.0%

Shareholding Pattern

Insiders
5.42%
Institutions
107.26%
Public Float
113.41%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.89% 2.96M $218.61M
2 Soleus Capital Management, L.P. 3.78% 867.76K $64.12M
3 Vanguard Capital Management LLC 3.65% 838.22K $61.94M
4 State Street Corporation 3.62% 831.65K $61.45M
5 Tang Capital Management, LLC 3.08% 707.50K $52.28M
6 Dimensional Fund Advisors LP 2.72% 623.46K $46.07M
7 American Century Companies Inc 2.50% 574.47K $42.45M
8 Arrowstreet Capital, Limited Partnership 2.45% 562.02K $41.53M
9 Global Alpha Capital Management Ltd. 2.43% 558.00K $41.23M
10 Geode Capital Management, LLC 2.34% 536.41K $39.64M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANIP

Yahoo Finance Fri, 23 Oct 2026

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a…

Yahoo Finance Mon, 19 Oct 2026

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI’s Duloxetine Delayed-Release Capsules a…

Yahoo Finance ue, 13 Oct 2026

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo Finance Mon, 12 Oct 2026

ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance1 at 6 months, and these changes were maintained at 24 months (a key secondary endpoint)…

Yahoo Finance Wed, 07 Oct 2026

Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?

ANI Pharmaceuticals recently received final U.S. FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension 2mg, 3mg, and 5mg, the generic version of Afinitor Disperz, entering a U.S. market with approx…

Yahoo Finance Wed, 30 Sep 2026

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026 Post-hoc analyses of baseline characteristics and efficacy outcomes in rescued and non-…

ANIP — Frequently Asked Questions

What is the current share price of ANI Pharmaceuticals, Inc. (ANIP)?

As of 2026-10-23 16:27 PDT, ANI Pharmaceuticals, Inc. (ANIP) trades at $72.61 on NasdaqGM. Its 52-week range is $70.16 to $98.81.

What is the market capitalisation of ANIP?

ANI Pharmaceuticals, Inc. (ANIP) has a market capitalisation of $1.67B on NasdaqGM.

What is the P/E ratio of ANIP?

ANIP trades at a trailing price-to-earnings (P/E) ratio of 15.72. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.65.

What is the return on equity (ROE) of ANIP?

ANIP has a return on equity (ROE) of 20.46%. Its return on capital employed (ROCE) is 6.99%.

Is ANIP a good stock to buy?

This page provides a data-driven analysis of ANI Pharmaceuticals, Inc. (ANIP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space